Skip to main content

The first university double blind study showing the efficacy of the Asyra Biofeedback technology proves the technology. The preliminary statistics of an allergy desensitisation study were just released from the university of Utah. The complete reporting is to follow soon. The study had 35 participants who were followed . All had sensitivities to airborne allergens. Blood markers were used prior and post Asyra treatment.

Only four Asyra treatments were given. These results compare with what we see in the office.

Allergy Desensitisation (4 visits)
Imprinted Remedies: Group 1-25 Active, 26-30 Placebo, 31-35 Control
Pre Study Post Study

Treatment Group 1-25 received an Asyra comprehensive analysis with airborne allergens profiles. This group received imprinted remedies. 95% showed dramatic reduction in blood antigens for allergies.

Placebo Group 26-30 received placebo remedies, this group showed less than one percent improvement.

Control Group 31-35 were the control and had no treatment. They had less than one percent improvement.

Red bars are blood markers at the beginning of the study prior to treatment. Green Bars are the blood studies after 4 treatments. I assume this was over a 4-5 month period.

All participants received an Asyra comprehensive analysis and airborne allergens profiles before during and at the end of the study.

More than 70 percent of patients in any general practice suffer from functional disturbances. Simply speaking, a functional disturbance occurs when no specific tissue or organ damage can be identified by conventional lab work or other pathological diagnostics, yet the patient still experiences a myriad of symptoms. Where traditional approaches end, the Asyra system introduces a new perspective for evaluating and developing solutions to these issues. This study although small appears quite conclusive that the Asyra has a powerful ability to reduce airborne allergy sensitivity.